Target intelligence / Profile preview

Cytomegalovirus DNA polymerase (UL54) (UL54)

Target
UL54
Molecular classification
Enzyme, DNA polymerase, Family B DNA polymerase
01

Overview

Cytomegalovirus (CMV) DNA polymerase, encoded by the UL54 gene, is a critical enzyme belonging to the Family B DNA polymerases, which are essential for the replication of the viral genome in herpesviruses (UniProt: P06477). The enzyme functions as a DNA-directed DNA polymerase, catalyzing the synthesis of viral DNA by incorporating deoxyribonucleoside triphosphates into the growing chain (PubMed: 11831707). It also possesses a 3'-5' exonuclease domain that provides proofreading capabilities, which is vital for maintaining the genetic integrity of the virus during rapid replication cycles. In clinical settings, this polymerase is the central target for treating infections caused by CMV and other herpesviruses, which can lead to severe morbidity in immunocompromised individuals and neonates (StatPearls: NBK499940). Drugs such as ganciclovir and cidofovir act as competitive inhibitors and DNA chain terminators after being phosphorylated by viral or cellular kinases (PubChem: CID 3454). Foscarnet provides an alternative mechanism by acting as a pyrophosphate analog that directly blocks the pyrophosphate binding site on the polymerase without requiring prior activation. The emergence of drug resistance is a major therapeutic challenge, typically involving point mutations in the UL54 gene that reduce the enzyme's affinity for antiviral agents (PubMed: 15917462).

Other names
DNA-directed DNA polymeraseHerpesvirus family B DNA polymeraseCMV PolUL54 gene product
02

Mechanism of action

Competitive inhibition of deoxyribonucleoside triphosphate (dNTP) incorporation and DNA chain termination

03

Biological functions

Viral DNA replicationDNA synthesis3'-5' exonuclease activityProofreading
04

Disease associations

InfectionCytomegalovirus infectionHerpes simplex virus infectionVaricella-zoster virus infectionEpstein-Barr virus infection
05

Safety considerations

NephrotoxicityMyelosuppressionElectrolyte imbalanceAntiviral resistanceTeratogenicity
06

Interacting drugs

Ganciclovir

4 more in the full profile.

07

Biomarkers

CMV DNA viral loadUL54 gene mutationsUL97 gene mutations

Beyond the preview

Go deeper on Cytomegalovirus DNA polymerase (UL54) (UL54).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytomegalovirus DNA polymerase (UL54) (UL54).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call